Decline in subarachnoid haemorrhage volumes associated with the first wave of the COVID-19 pandemic


© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to
Dr Raul G Nogueira;
raul.g.nogueira@emory.edu

ABSTRACT

Background During the COVID-19 pandemic, decreased volumes of stroke admissions and mechanical thrombectomy were reported. The study’s objective was to examine whether subarachnoid haemorrhage (SAH) hospitalisations and ruptured aneurysm coilings demonstrated similar declines.

Methods We conducted a cross-sectional, retrospective, observational study across 6 continents, 37 countries and 140 comprehensive stroke centres. Patients with the diagnosis of SAH, aneurysmal SAH, ruptured aneurysm coilings and COVID-19 were identified by prospective databases or by International Classification of Diseases, 10th Revision, codes. The 3-month cumulative volume, monthly volumes for SAH hospitalisations and ruptured aneurysm coilings were compared for the period before (1 year and immediately before) and during the pandemic, defined as 1 March–31 May 2020. The prior 1-year control period (1 March–31 May 2019) was obtained to account for seasonal variation.

Findings There was a significant decline in SAH hospitalisations, with 2044 admissions in the 3 months immediately before and 1585 admissions during the pandemic, representing a relative decline of 22.5% (95% CI −24.3% to −20.7%, p<0.0001). Embolisation of ruptured aneurysms declined with 1170–1035 procedures, respectively, representing an 11.5% (95% CI −13.5% to −9.8%, p=0.002) relative drop. Subgroup analysis was noted for aneurysmal SAH hospitalisation decline from 834 to 626 hospitalisations, a 24.9% relative decline (95% CI −28.0% to −22.1%, p<0.0001). A relative increase in ruptured aneurysm coilings was noted in low coiling volume hospitals of 41.1% (95% CI 32.3% to 50.6%, p=0.008) despite a decrease in SAH admissions in this tertile.

Interpretation There was a relative decrease in the volume of SAH hospitalisations, aneurysmal SAH hospitalisations and ruptured aneurysm embolisations during the COVID-19 pandemic. These findings in SAH are consistent with a decrease in other emergencies, such as stroke and myocardial infarction.

BACKGROUND

The COVID-19 pandemic led to the rationing of healthcare resources worldwide to accommodate the care of critically ill patients with SARS-CoV-2 infection. Changes in prehospital emergency medical service, emergency room care, acute stroke and subarachnoid haemorrhage (SAH) protocols were reported to conserve resources and to mitigate infection risk to patients and their providers. Decreases in ischaemic stroke admission, rates of intravenous thrombolysis (IVT), and mechanical thrombectomy (MT) volumes were reported in several regions in Europe, Germany, China, Brazil and the USA, with steeper declines in stroke hospitalisations in areas with higher COVID-19 hospitalisation volume.

However, there is a paucity of information on the impact of the COVID-19 pandemic on SAH admissions. Early regional or single-centre reports from Paris and Toronto suggest a decrease in aneurysmal SAH volumes, whereas no changes were seen in Berlin. We evaluated the impact of COVID-19 on the volumes of SAH admissions and embolisation treatments for patients with ruptured intracranial aneurysms during the height of the first 3 months of the pandemic, defined from 1 March to 31 May 2020.

Study objectives and hypothesis

Our primary hypothesis was that there would be a reduction in SAH hospitalisations and endovascular coil embolisation procedures for ruptured aneurysms during the pandemic, compared with the immediate 3 months prior to the pandemic. Our secondary hypothesis was that there would be a reduction in these volumes compared with a similar calendar period in 2019. The third hypothesis was that the reduction in SAH volume would occur in most centres, including those with low or non-existent COVID-19 hospitalisation burden, but would be more significant in centres with high COVID-19 hospitalisation burden. The fourth hypothesis was that high procedural coil embolisation volume centres would be less impacted by procedural volume compared with low procedural volume centres.

METHODS

Study design

This was a cross-sectional, observational, multicentre, retrospective study of consecutive patients hospitalised with SAH, aneurysmal SAH, non-traumatic SAH and ruptured intracranial aneurysm embolisations.

Setting and participants

Of 175 invited sites, 140 comprehensive stroke centres submitted data from 37 countries across six continents with 5571 patients with SAH and 3473 ruptured aneurysm embolisations across the three different study periods. Monthly and weekly volume of SAH, ruptured aneurysm embolisations and COVID-19 admission volume data were collected over three periods of time: 1 March–31 May 2020 (pandemic months), 1 November 2019–29 February 2020 (immediately preceding the pandemic months) and 1 March–31 May 2019 (equivalent period 1 year prior to the pandemic). The period of recruitment was conducted between 26 May and 30 July 2020. The data were collected on Excel (version 16.45) documents.
Table 1  SAH hospitalisation volumes immediately before and during the COVID-19 pandemic

<table>
<thead>
<tr>
<th></th>
<th>Overall volume</th>
<th>Monthly volume</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>n1</td>
</tr>
<tr>
<td>Overall</td>
<td>118</td>
<td>2044</td>
</tr>
<tr>
<td>Hospital COVID-19 volume†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>32</td>
<td>432</td>
</tr>
<tr>
<td>Int</td>
<td>32</td>
<td>589</td>
</tr>
<tr>
<td>High</td>
<td>33</td>
<td>731</td>
</tr>
<tr>
<td>Hospital SAH coil embolisation volume‡</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>42</td>
<td>370</td>
</tr>
<tr>
<td>Int</td>
<td>35</td>
<td>490</td>
</tr>
<tr>
<td>High</td>
<td>35</td>
<td>1014</td>
</tr>
</tbody>
</table>

n1 is based on 3 months before the pandemic (December 2019–February 2020). Immediately before is based on 4 months before the pandemic (November 2019–February 2020); n2 and during COVID-19 are based on March 2020–May 2020. P value is from Poisson means test (overall volume analysis) and Wilcoxon signed-rank test (monthly volume analysis).

*Difference denotes the median difference between the two time periods.
†P value: low versus Int=0.004, low versus high=0.0001, Int versus high=0.002.
‡P value: low versus Int=0.831, low versus high=0.429, Int versus high=0.541.
Int, intermediate; N, number of hospitals; n, number of admissions; SAH, subarachnoid haemorrhage.

Data were collected from collaborators of the Society of Vascular and Interventional Neurology, the Middle East North Africa Stoke and Interventional Neurotherapies Organisation, the Japanese Interventional Neurology Society and several academic partners. The following countries were represented (number of centres): USA (45), Japan (30), China (6), Brazil (6), Canada (6), France (4), Australia (3), Korea (3), India (3), Chile (2), Spain (2), Switzerland (2), England (2), Saudi Arabia (2), Turkey (2), Austria (1), Argentina (1), Egypt (1), Germany (1), Vietnam (1), Croatia (1), Greece (1), Indonesia (1), Ireland (1), Israel (1), Italy (1), Lebanon (1), New Zealand (1), Oman (1), Pakistan (1), Portugal (1) Qatar (1), South Africa (1), Thailand (1), Tunisia (1), United Arab Emirates (1) and Uruguay (1).

Study variables and outcome measures

SAH data were obtained by a prospectively maintained aneurysm or stroke databases at each comprehensive stroke centre or by International Classification of Diseases, 10th Revision (ICD-10) codes (primary, secondary or tertiary discharge codes) with verification by a physician or coordinator. The following ICD-10 codes were used: I60 (non-traumatic SAH), I60.0 (non-traumatic SAH from carotid siphon and bifurcation), I60.1 (non-traumatic SAH from middle cerebral artery), I60.2 (non-traumatic SAH from anterior communicating artery), I60.3 (non-traumatic SAH from posterior communicating artery), I60.4 (non-traumatic SAH from basilar artery), I60.5 (non-traumatic SAH from vertebral artery), I60.6 (non-traumatic SAH from other intracranial arteries), I60.7 (non-traumatic SAH from intracranial artery, unspecified) I60.8 (other non-traumatic SAH) and I60.9 (non-traumatic SAH unspecified).

Subgroup analysis of confirmed aneurysmal SAH hospitalisations and non-traumatic SAH were performed. Aneurysmal SAH was defined as SAH related to a ruptured intracranial aneurysm. Non-traumatic SAH was defined as SAH unrelated to traumatic causes but could include SAH secondary to aneurysmal, arteriovenous malformation (AVM), perimesencephalic or other causes. The volume of embolisations of ruptured intracranial aneurysms was also retrieved.

COVID-19 hospitalisation was defined as a patient admitted with COVID-19 diagnosis, inclusive of non-neurological diagnosis. Monthly and weekly volumes of COVID-19 hospitalisation were collected from 1 March to 31 May 2020.

Low, intermediate and high procedural volume centres were categorised according to monthly coiling of ruptured aneurysm volume data received of the 4 months immediately preceding the pandemic (1 November 2019–29 February 2020, inclusive) and divided into tertiles: low volume, <1.25; intermediate volume, >1.25–<3.0; and high volume, >3 coiling cases per month. COVID-19 hospitalisation volumes were based on mean monthly volume data received and were divided into tertiles: low volume, <10.6; intermediate volume, >10.6–<103.6; and high volume, >103.6 hospitalisations per month.

Bias

A second control period (1 March–31 May 2019) was included to account for seasonal variation. To reduce the risk of bias, centres with incomplete data were excluded from the subgroup analysis in which the data were missing.
Statistical analysis
The monthly volumes for the ruptured aneurysm coil embolisation procedure and SAH admissions were compared for the period before (1 year and immediately before) and during the COVID-19 pandemic. The normality of the data was tested with the Shapiro-Wilk test. The data were determined to be non-normal and were therefore presented as median (IQR). The non-parametric Wilcoxon signed-rank test was applied to compare differences in monthly volume between two time periods. The analyses were repeated in the setting of low, intermediate and high COVID-19 and procedural volume hospitals.

We further looked at the percentage change in the number of procedures and SAH admissions, aneurysmal SAH admissions, and non-traumatic SAH admissions before and during the COVID-19 pandemic. For this analysis, we restricted the immediately before group to 3 months before the pandemic (1 December 2019–29 February 2020) to keep it consistent with the COVID-19 group. The 95% CIs for percentage change were calculated using the Wilson procedure without correction for continuity. The differences in the number of procedures and admissions across the two periods were assessed for significance using the Poisson means test. The relative percentage decrease in volume between low-volume, intermediate-volume and high-volume hospitals was tested using the z-test of proportion.

We performed a supplementary analysis comparing monthly volumes and percentage change in the number of ruptured aneurysm coiling procedures and SAH hospitalisations across different world regions. All data were analysed using SAS V.9.4, and the significance level was set at a p value of <0.05.

This study is reported in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology guidelines.19

FINDINGS
A total of 1088, 2044 and 1585 SAH hospitalisations (overall n=4717) and 719, 1170 and 1035 coiling procedures for ruptured aneurysms (overall n=2924) were included across the 3-month prior year periods, 3 months immediately prepandemic and 3 months pandemic, respectively. These were distributed across 140 comprehensive stroke centres, 37 nations and 6 continents. The Shapiro-Wilk test revealed that the normality of the data was non-normal.

Subarachnoid hemorrhage hospitalisation volumes
In the primary analysis, 118 centres submitted data on SAH volume with a total of 2044 admissions in the 3 months immediately before and 1585 admissions during the 3 months of the pandemic, representing a relative volume decline of 22.5% (95% CI −24.3% to −20.7%, p<0.0001). Monthly SAH admission volumes also demonstrated a relative decline before and during the pandemic months (median, 4.5 (IQR 2.5–7.1) vs 3.3 (IQR 1.3–6.3); p<0.0001) (table 1 and figure 1).

In the secondary analysis, 75 centres contributed data with SAH monthly volumes 1 year prior (table 2). There were 1088 before, compared with 900 SAH admissions during the pandemic, representing a 17.3% relative decline (95% CI, −19.6 to −15.2, p<0.0001). The
median monthly SAH admission volume declined from a median of 3.0 [IQR, 2.0–6.3] in the corresponding period of the prior year to 2.7 [IQR, 1.3–5.7, p=0.001] over the first 3 months of the pandemic.

In subgroup analysis, 56 centres confirmed aneurysmal SAH admissions data in the 3 months immediately before and during the pandemic. There was a relative decline from 834 to 626 hospitalisations, representing a 24.9% relative decline (95% CI –28.0% to –22.1%, p<0.0001). Additionally, 37 centres confirmed aneurysmal SAH admissions data in the 1-year prior control period, also noted for a relative decline from 435 to 370 hospitalisations, representing a 14.9% relative decline (95% CI –18.6 to –11.9, p=0.022) (table 3).

Non-traumatic SAH admissions had parallel relative declines both in the immediately before (–24.6%, 95% CI –26.9% to –22.5%, p<0.0001, n=85 centres) and 1-year before periods (–15.6%, 95% CI –18.4% to –13.1%, p=0.002, n=53 centres) (table 3).

Declines in SAH hospitalisation volumes were significant in Asia, with a relative decrease of 24.7% (95% CI –28.0% to –21.7%, p<0.0001, n=47 centres); North America, with a relative decrease of 21.0% (95% CI –24.0% to –18.3%, p<0.0001, n=46 centres); Europe, with a relative decrease of 29.0% (95% CI –35.3% to –23.5%, p=0.001, n=11 centres); South America, with a relative decrease of 21.5% (95% CI –27.4% to –16.6%, p=0.012, n=8 centres). In contrast, no significant change was noted in Oceania or Africa. (online supplemental table 1). Country-specific relative changes in SAH hospitalisation volumes are represented in online supplemental table 3 and online supplemental figure 1).

### SAH aneurysm embolisation volumes

In the primary analysis, 125 centres submitted data on ruptured aneurysm embolisation volumes with a total of 1170 procedures in the 3 months immediately before and 1035 procedures performed during the 3 months of the pandemic, representing a relative drop of 11.5% (95% CI –13.5% to –9.8%, p=0.002). Median monthly embolisation volumes demonstrated a relative decline compared with the same periods immediately preceding (median, 1.8 (IQR 1–4) vs 1.7 (IQR 0.67–3.7); p=0.004) (table 4 and figure 1).

In the secondary analysis, 83 centres contributed data for ruptured aneurysm coiled volumes during the pandemic and 1 year previously. Ruptured aneurysm embolisations also declined numerically between the calendar year, 719 vs 652 procedures, with a 9.3% (95% CI –11.7% to –7.4%, p=0.07) relative drop in volumes (table 2). No significant change was noted in the median monthly volume (p=0.197).

During the pandemic, ruptured aneurysm coiling volume was decreased in Asia with a 20.5% relative decline (95% CI –24.9% to –16.6%, p=0.003, n=52 centres), decreased in Europe with a 15.3% relative decline (95% CI –20.4% to –11.3%, p=0.06, n=14...
centres) and increased in Oceania by 77.8% (95% CI 54.8 to 91.0, p=0.06, n=4 centres), whereas no significant change in volume was noted in North America, South America nor Africa (online supplemental table 2). Country-specific relative changes in ruptured aneurysm coiling volumes are represented in online supplemental table 3 and online supplemental figure 2.

COVID-19 hospitalisation volume, SAH hospitalisation and ruptured aneurysm embolisation volumes in relation to the pandemic

Figure 1 depicts the weekly number of SAH hospitalisations, ruptured aneurysm coiling and COVID-19 hospitalisation volumes. Across the tertiles of COVID-19 hospitalisation volume, high-volume COVID-19 centres (−29.8%, 95% CI −33.2% to −26.6%) were significantly more vulnerable to declines in SAH hospitalisation volumes than low-volume COVID-19 centres (−15.1%, 95% CI −18.7% to −12.0%; p<0.0001) (table 1).

Similarly, there was a gradient for greater decrease in ruptured aneurysm embolisation in high-volume COVID-19 centres (−22.2%, 95% CI −27.0% to −18.0%) compared with intermediate-volume (−10.0%, 95% CI −13.8% to −7.2%, p<0.0001) and low-volume (−1.5%, 95% CI −3.7% to −0.6%, p<0.001) COVID-19 centres (table 4).

Ruptured aneurysm procedural volumes, SAH hospitalisation and ruptured aneurysm embolisation volumes in relation to the pandemic

There were declines in SAH hospitalisation volume across the three tertiles of high (−22.8%, 95% CI −25.5% to −20.3%, p<0.0001), intermediate (−21.4%, 95% CI −25.3% to −18.0%, p=0.0002) and low (−20.8%, 95% CI −25.2% to −17.0%, p=0.002) SAH procedural volume centres, with no differences in decline seen between the three tertiles (table 1).

Similarly, ruptured aneurysm embolisation volume declines were noted in high (−18.2%, 95% CI −20.9% to −15.8%, p<0.0001) procedural volume centres. However, in hospitals with low tertile procedural volumes, there was an increase noted in the coiling of the ruptured aneurysm during the pandemic of 41% (95% CI 32.3% to 50.6%, p=0.008) (table 4).

DISCUSSION

We noted a decrease in the volume of SAH hospitalisations, aneurysmal SAH hospitalisations and embolisation of ruptured aneurysms during the first 3 months of the COVID-19 pandemic compared with the immediate prior months. Compared with the corresponding period in the prior year, there was a significant reduction in SAH hospitalisation volume, but no change was noted in the number of embolisation procedures for ruptured aneurysms. To our knowledge, this is the first report of a multicentre decrease in volumes for SAH hospitalisations, aneurysmal SAH hospitalisations and embolisation procedures for ruptured intracranial aneurysm during the COVID-19 pandemic.

Table 3: Aneurysmal SAH, non-traumatic SAH hospitalisations before and during the pandemic

<table>
<thead>
<tr>
<th></th>
<th>Immediately before the pandemic</th>
<th>During the pandemic</th>
<th>Relative change % (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aneurysmal SAH</td>
<td>n=56</td>
<td>n=834</td>
<td>−24.9 (−28.0 to −22.1)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Non-traumatic SAH*</td>
<td>n=85</td>
<td>n=1451</td>
<td>−24.9 (−26.9 to −22.5)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

n1 immediately before the pandemic is based on 3-month data from December 2019 to February 2020. n1 1 year before is based on 3-month data from March 2019 to May 2020 for both analyses. n2 is based on 3-month control data during the COVID-19 from March 2020 to May 2020 for both analyses. n, number of admissions; N, number of hospitals; SAH, subarachnoid haemorrhage. *Non-traumatic SAH include aneurysms and perimesencephalic SAH.

Table 4: COVID-19 hospitalisation and ruptured aneurysm embolisation volumes in relation to the pandemic

<table>
<thead>
<tr>
<th></th>
<th>Immediately before the pandemic</th>
<th>During the pandemic</th>
<th>Relative change % (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aneurysmal SAH</td>
<td>n=37</td>
<td>n=435</td>
<td>−14.9 (−18.6 to −11.9)</td>
<td>0.002</td>
</tr>
<tr>
<td>Non-traumatic SAH*</td>
<td>n=37</td>
<td>n=435</td>
<td>−15.6 (−18.4 to −13.1)</td>
<td>0.002</td>
</tr>
</tbody>
</table>

n1 immediately before the pandemic is based on 3-month data from December 2019 to February 2020. n1 1 year before is based on 3-month data from March 2019 to May 2019, n2 is based on 3-month data from March 2020 to May 2020 for both analyses. n, number of admissions; N, number of hospitals; SAH, subarachnoid haemorrhage. *Non-traumatic SAH include aneurysms and perimesencephalic SAH.
Table 4  
SAH coil embolisation volumes immediately before and during the COVID-19 pandemic

<table>
<thead>
<tr>
<th>Overall volume</th>
<th>Monthly volume</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Overall</td>
</tr>
<tr>
<td>N</td>
<td>n1</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Overall</td>
<td>125</td>
</tr>
<tr>
<td>Hospital COVID-19 volume†</td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>39</td>
</tr>
<tr>
<td>Int</td>
<td>33</td>
</tr>
<tr>
<td>High</td>
<td>31</td>
</tr>
<tr>
<td>Hospital SAH Coil embolisation volume‡</td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>46</td>
</tr>
<tr>
<td>Int</td>
<td>37</td>
</tr>
<tr>
<td>High</td>
<td>42</td>
</tr>
</tbody>
</table>

n1 is based on 3 months before the pandemic (December 2019–February 2020). Immediately before is based on 4 months before the pandemic (November 2019–February 2020). n2 and during COVID-19 are based on March 2020–May 2020. P value is from Poisson means test (overall volume analysis) and Wilcoxon signed-rank test (monthly volume analysis). *Difference denotes the median difference between the two time periods. †P value: low versus Int, n/a; low versus high, 0.0001; Int versus high, 0.0001. ‡P value: low versus Int, n/a; low versus high, n/a; Int versus high, 0.019. Int, intermediate; N, number of hospitals; n, number of procedures; n/a, not applicable; SAH, subarachnoid haemorrhage.
pandemic. Our findings are similar to reported decreases in SAH city-wide in Paris during a 2-week period of the pandemic\textsuperscript{16} and decreases in a Toronto hospital,\textsuperscript{17} whereas Berlin and Joinville, South Brazil, reported no decreases in SAH during the COVID-19 pandemic.\textsuperscript{12,18}

As expected, hospitals with higher tertiles of COVID-19 hospitalisation burden were more vulnerable to the decline in SAH admissions and ruptured aneurysm coiling volume. However, hospitals with lower COVID-19 hospitalisation burden also demonstrated decreases in SAH admissions, suggesting that access to hospital care was likely not a principal factor to explain the decrease.

High and intermediate procedural volume centres were more affected by declines in SAH hospitalisations and ruptured aneurysm embolisation than low-volume SAH coiling centres during the pandemic. In contrast, hospitals with low SAH coiling volumes at baseline demonstrated an increase in the coiling of ruptured aneurysms during the pandemic despite a significant decrease in total SAH admissions within this tertile of hospitals. An increase in ruptured aneurysm embolisations was observed in another recent multicentre study during the COVID-19 pandemic.\textsuperscript{20} This suggests a shift towards treating more patients with ruptured aneurysms with endovascular techniques during the pandemic, possibly to mitigate risks of perioperative infection to the patient and/or provider.

These findings of decreases in SAH volumes, including embolisation of ruptured aneurysms, are similar to reports of decreases in stroke admissions, intravenous thrombolysis, MT and acute ST-elevation myocardial infarction (STEMI) activations during the COVID-19 pandemic.\textsuperscript{10,13,21} As postulated with reasons for the decline in stroke admissions in the stroke literature,\textsuperscript{8} patients with milder presentations of aneurysmal SAH may be afraid to present to a hospital due to fear of contracting SARS-CoV-2 infection.

This analysis’s strength is the aggregate volume of data worldwide across diverse geography, allowing a high volume or sample size. We used two control periods for comparison; the immediately preceding 3 months and the same 3 months a year ago, to account for potential seasonal variations that may occur in the presentation of SAH.\textsuperscript{22}

**Study limitations**

This study’s limitations are that while our cohort of centres inform an international, multicentre experience, it is not comprehensive without source data from national databases to account for regional differences in health systems of care. The diagnosis of SAH was obtained using ICD-10 codes in some centres. We cannot exclude the possibility of traumatic SAH. To differentiate from this possibility, we performed a subgroup analysis of confirmed aneurysmal SAH and non-traumatic SAH admissions and found similar relative declines in both control periods. Most centres contributing to these data have systems in place to track SAH admissions and coiling volumes; hence, the relative changes in volume from this analysis are likely robust. Details on patient SAH presentation grade, clinical outcomes and clipping volume were not collected as they were outside the scope of the study.

Our study definition of the beginning of the pandemic relates to the WHO designation on 11 March 2020. However, regions affected by the pandemic earlier, such as China, met the nadir of their SAH volumes prior to starting our defined pandemic period. As endovascular coiling remains unavailable in many low-income and lower-income to middle-income countries, specific geographical regions were not well represented (ie, Central Africa) in our study. Another shortcoming in selection bias is that several countries in which endovascular coiling is available were not represented in this study (ie, Eastern Europe, South America, Central America and Asia).

**INTERPRETATION**

In conclusion, there was a relative decrease in the volume of SAH hospitalisations, aneurysmal SAH hospitalisations and ruptured aneurysm embolisation treatments during the first 3 months studied of the COVID-19 pandemic. There were steeper relative declines in SAH hospitalisations and SAH coiling volume in hospitals with higher COVID-19 volume. Among low-volume coiling SAH hospitals, there was a shift towards an increase in ruptured aneurysm coiling. These findings can inform regional neuroscience centres’ preparedness\textsuperscript{23,24} in the face of a potential second wave or resurgence of COVID-19.

**Author affiliations**

1Neurology, Radiology, Boston Medical Center, Boston, Massachusetts, USA
2Neurology, Marcus Stroke & Neuroscience Center, Grady Memorial Hospital, Emory University School of Medicine, Atlanta, GA, USA
3Radiology, Radiation Oncology, Boston University School of Medicine, Boston, Massachusetts, USA
4Neurology, National Hospital Organization Osaka National Hospital, Osaka, Japan
5Neurosurgery, National Hospital Organization Osaka National Hospital, Osaka, Japan
6Neurology, Alexandria University, Alexandria, Egypt
7Radiology, Boston Medical Center, Boston, Massachusetts, USA
8Department of Neurology, Xinqiao Hospital, Chongqing, China
9Neurosurgery, University of Cape Town, Rondebosch, Western Cape, South Africa
10Neurosurgery, Interventional Neuroradiology, Clinica La Sagrada Familia, Buenos Aires, Argentina
11Neuroradiologie, Neuroradiologie Vasculaire, Hospices Civils de Lyon, Lyon, Auvergne-Rhône-Alpes, France
12Neurologie Vasculaire, Hospices Civils de Lyon, Lyon, Auvergne-Rhône-Alpes, France
13Interventional Neuroradiology, Fondation Ophthalmologique Adolphe de Rothschild, Paris, Île-de-France, France
14Neurology, Hospital Geral de Fortaleza, Fortaleza, Brazil
15Interventional Neuroradiology, Hospital Geral de Fortaleza, Fortaleza, Brazil
16Neuroradiology, Nottingham University Hospitals NHS Trust, Nottingham, UK
17Department of Neurosurgery, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan
18Interventional Neuroradiology, University Hospital Careggi, Firenze, Toscana, Italy
19Neuroradiology, University Hospital Centre Zagreb, Zagreb, Croatia
20Interventional Neuroradiology, Hospital Bicêtre, La Kremlin-Bicêtre, France
21Stroke and Interventional Neuroradiology, Lahore General Hospital, Lahore, Pakistan
22Neurological Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, UAE


Open access
12Interventional Neuroangiography, University of California Los Angeles, Los Angeles, California, USA
12Neurology, Erlanger Medical Center, University of Tennessee, Chattanooga, Tennessee, USA
12Neurology, Neurosurgery, Radiology, University of Texas Health San Antonio, San Antonio, Texas, USA
12Neurology, Mianyang 404 Hospital, Mianyang, Sichuan, China
12Radiology, Siriraj Hospital, Mahidol University, Bangkok, Thailand
12Neurology, Neurosurgery, Radiology, SONY Upstate Medical University, Syracuse, New York, USA
12Neurosurgery, Royal North Shore Hospital, Sydney, New South Wales, Australia
12Neurosociences, The University of Texas Rio Grande Valley, Harlingen, Texas, USA
12Central Stroke Unit, Directorate of Neurosciences, Khoulia Hospital, Ministry of Health, Muscat, Oman
12Neurology, University of Michigan, Ann Arbor, Michigan, USA
12Neurosurgery, University of South Florida, Tampa, Florida, USA
12Neurology, Henry Ford Health System, Detroit, Michigan, USA
12Stroke Unit, Metropolitan Hospital, Piraeus, Greece
12Faculty of Medicine, National and Kapodistrian University of Athens, Athens, Greece
12Neurology, Maine Medical Center, Portland, Maine, USA
12Neuroangiography, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA
12Neurology, Hospital Universitario de Brasilia, Brasilia, Distrito Federal, Brazil
12Neurointerventional Neurosurgery, The Valley Hospital, Ridgewood, New Jersey, USA
12Neurosociences, Stroke Program, St Joseph’s University Medical Center, Paterson, New Jersey, USA
12Neurology, Christian Medical College and Hospital Ludhiana, Ludhiana, Punjab, India
12Vascular Neurology Unit, Clinica Alemana, Universidad del Desarrollo, Santiago, Chile
12Neurology, Osaka University Graduate School of Medicine, Osaka, Japan
12Neurology, Tokushima University Hospital, Tokushima, Japan
12Neurology, Universidad Federale de Sao Paulo, Sao Paulo, Sao Paulo, Brazil
12Istanbul Aydin University, Istanbul, Istanbul, Turkey
12Neurology, Bayhealth Medical Center, Dover, Delaware, USA
12Neurology, Saiseikai Fukuoka General Hospital, Fukuoka, Japan
12Division of Stroke, Department of Internal Medicine, Osaka Rosai Hospital, Saka, Osaka, Japan
12Neurology Division, Department of Medicine, King Saud University, Riyadh, Riyadh Province, Saudi Arabia
12Neurology, Mount Sinai Health System, New York, New York, USA
12Neurology, Clinical Neurosciences and Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada
12Neurology, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
12Neurology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China
12Neurology, Yijishan Hospital of Wannan Medical College, Wuhu, Anhui, China
12The University of Toledo, Toledo, Ohio, USA
12Neuroscience, WellStar Health System, Marietta, Georgia, USA
12Neuroangiologie Interventioneille, Centre Hospitalier de l’Université de Montréal, Montréal, Quebec, Canada

Twitter Thanh N Nguyen @NguyenThanhMD, Diogo C Haussen @DiogoHaussen, Ossama Y Mansour @OssamaMansour, Mohamed Abdalkader @AbdalkaderMD, Pedro Lylyk @eneri_neuro, Mahmoud Mohammaden @MahmoudNeuro, Alhamza R Al-Bayati @AABAlBayati1, Saima Ahmad @SaimaAh46545828, Rodrigo Rivera @neurofox, Huynh Le Vu @DrLe2287, Viet G Nguyen @VqetNguyen, Romain Bourricourt @bourricourromain1, Malveeka Sharma @MalveekaSharma @Malveeka2013, Don Frei @donfreid, Pascal Jabbour @PascalJabbourMD, Nabeel Herial @NabeelHerial, Fawaz Al-Mufi @alMufiFawaz, Dheeraj Gandhi @dgandhimd, Charles Hamden @CharlesHamden, Michael Chen @mchen_mchen, Vitor Mendes Pereira @VitorMendesPer1, Patrick Nicholson @paddynicholson, Pedro SC Magalhaes @Neuropanda, Raghid Kikano @Raghidkikano, Santiago Ortega-Gutierrez @CerebrovascLab, Amal Abou-Hamed @IAANeurosurgeon, Adrienne Weeks @Operatingheels, Elena A Cora @esacora, Simon Nagel @NagelSimon, Hosam Al-Jehani @HosamAlJehani, Sunil A Sheth @SunilAShethMD, James E Sieler @JimSieler, Ajit S Puri @AjitS PURI, Gianmarco Berna @GianmarcoBerna5, Daniel G Abud @neuroabud, Octavio M Pontes-Neto @PontesnetoMD, Eytan Raz @eytanraz, Shadi Yaghil @ShadiYaghil2, Brijesh P Mehta @NeuroINX, Steve M Cordina @SteveCordina, Juan F Arellanas @ArellinasJF, Mario Martinez-Galdamez @DoctorGaldamez, Joridi Blasco @jorblascos, Teddy Y Wu @teddywuhy, Marios Psychoglou @MPeyT1, Roberta Novakovic @Robin_Novakovic, Michael Kelly @michaelbekely, Hugh Stephen Winters @stephen_winters, Mohamed Tlef @StrokeWAN, Vasu Saini @VSainimD, Dileep Yavagal @dyavagayal, Italo Lintante @italoLintante, David S Liebeskind @dliebesk, Viktor Szered @dvkvitsz, Ramez E Masoud @RamezMasoud, Brendan Steinfort @brendan_dr, Alice Ma @Alicemonica, Ameer E Hassan @AmeerEhassan, Maxim Mokin @MokinMax, Alex Chebel @AlexChebel, Odysseas Kargiotis @OKargiots, Dorothea Atsalch @DrAtsalch, Anirudh Kulkarni @anirudhK, Pablo M Lavados @pllavalamado, Veronica V Olavarria @volavarria, Gisela Sampaio Silva @GiselaSampaio, Artem Kaliva @artemka__crh, Adel Alhazzani @AdelALHAZZANI, David Y Chung @chungmdph, Stephan A Mayer @stephanemayer, Johanna T Fifi @johannatfifi, Michael D Hill @mhill88, Tudor G Jovin @TudorGlovin and Osama O Zaidat @oozaidat

Acknowledgements The authors thank Judith Clark, RN, Boston Medical Center; Matt Metzinger, MBA, CPH, Kamila Patel, RN, MSN, MBA, CPHQ, Jefferson; Janis Ginnane, RN, Emory University Hospital.

Contributors TNN and RGN conceived the project. They wrote the first draft of the paper with subsequent input from all coauthors. All coauthors played a major role in data acquisition and revision of the manuscript. MMO was the lead statistician for this study and performed the analysis. MA prepared the global maps in the supplement.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial, or not-for-profit sectors.

Competing interests TNN: PI CLEAR study (Medtronic). DCH: Stryker, Valsalio, Cerenovus consultant. AEH: consultant and speaker for Medtronic, Stryker, Microvention, Penumbra, Balt, Sientec, Medtronic, Medtronic, Microvention, Balt, Cerestech, Medtronic, Consultant. SS-G: Medtronic, Stryker consultant. DSL: Cerestech, Genentech, Stryker, Medtronic consultant. TGJ: advisor/investor for Anacoda, ROUTE2, FreeOx, and Blockade Medical; Medtronic grants, DAWN, AURORA PI (Stryker). WJM: consultant: Rebound Therapeutics, Viseon Investor for Anaconda, Route92, FreeOx, and Blockade Medical; Medtronic grants, IMPERATIVE CARE, O’apel, Stryker, Stream Biomedical, Spartan Micro; Investor: Cerebrotecth, Endostream, O’apel, Viseon, Rebound, and Spartan Micro. RGN: Stryker; Cerestech; Neuravi/Anacoda; Cerebrotech, Ceretrieve, Valsalio (Advisory Board); Imperative Care.

Patient consent for publication Not required.

Ethics approval The institutional review boards (IRBs) from the coordinating sites determined that because the investigators did not have access to protected health information or any private identifiable information, the study did not meet the definition of human subject research and therefore no informed consent or IRB oversight was first required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information. Anonymised data are available upon reasonable request from the corresponding author.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID ids Thanh N Nguyen http://orcid.org/0000-0002-2810-1685
Mohamed Abdalkader http://orcid.org/0000-0002-9528-301X
Laura Mechottr http://orcid.org/0000-0001-9165-5763
Pascal Jabbour http://orcid.org/0000-0002-8965-2413
Teddy Y Wu http://orcid.org/0000-0003-1845-1769
Ameer E Hassan http://orcid.org/0000-0002-7148-7616

REFERENCES
2 Nguyen TN, Jadhav AP, Dasenbrock HH et al. Subarachnoid hemorrhage guidance in the era of the COVID-19 pandemic - An...


